AstraZeneca will stop selling its breast cancer drug Nolvadex (tamoxifen) by the end of June, according to a letter posted on the FDA’s Web site this week. “As you know, currently there are numerous ...
From October 1 breast cancer drug Nolvadex (Tamoxifen) will be available on the Pharmaceutical Benefits Scheme (PBS) to prevent breast cancer, at present it is only subsidised for treating breast ...
Tamoxifen (Nolvadex) is an antiestrogen, prescribed for breast cancer. It is also used for infertility, gynecomastia, ductal carcinoma either alone or with other medications. It blocks the actions of ...
AstraZeneca is discontinuing US sales of its cancer drug Nolvadex (tamoxifen) from June, after mounting competition from generic products has substantially eroded sales of the brand. AstraZeneca is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results